Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glinsky, G. V.
Right arrow Articles by Glinskii, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glinsky, G. V.
Right arrow Articles by Glinskii, A. B.
Clinical Cancer Research Vol. 10, 2272-2283, April 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Classification of Human Breast Cancer Using Gene Expression Profiling as a Component of the Survival Predictor Algorithm

Gennadi V. Glinsky, Takuya Higashiyama and Anna B. Glinskii

Sidney Kimmel Cancer Center, San Diego, California

ABSTRACT

Purpose: Selection of treatment options with the highest likelihood of successful outcome for individual breast cancer patients is based to a large degree on accurate classification into subgroups with poor and good prognosis reflecting a different probability of disease recurrence and survival after therapy. Here we propose a breast cancer classification algorithm taking into account three main prognostic features determined at the time of diagnosis: estrogen receptor (ER) status; lymph node (LN) status; and gene expression signatures associated with distinct therapy outcome.

Experimental Design: Using microarray expression profiling and quantitative reverse transcription-PCR analyses, we compared expression profiles of the 70-gene breast cancer survival signature in established breast cancer cell lines and primary breast carcinomas from cancer patients. We classified 295 breast cancer patients using 14-, 13-, 6-, and 4-gene survival predictor signatures into subgroups having statistically distinct probability of therapy failure (P < 0.0001). We evaluated the prognostic power of breast cancer survival predictor signatures alone and in combination with ER and LN status using Kaplan-Meier analysis.

Results: The breast cancer survival predictor algorithm allowed highly accurate classification into subgroups with dramatically distinct 5- and 10-year survival after therapy of a large cohort of 295 breast cancer patients with either ER+ or ER– tumors as well as LN+ or LN– disease (P < 0.0001, log-rank test).

Conclusions: Our data imply that quantitative laboratory tests measuring expression profiles of a limited set of identified small gene clusters may be useful in stratification of breast cancer patients at the time of diagnosis into subgroups with statistically distinct probability of positive outcome after therapy and assisting in selection of optimal treatment strategies. The estimated increase in survival due to the optimization of treatment protocols may reach many thousands of breast cancer survivors every year at the 10-year follow-up check point.




This article has been cited by other articles:


Home page
JCOHome page
G. V. Glinsky
"Stemness" Genomics Law Governs Clinical Behavior of Human Cancer: Implications for Decision Making in Disease Management
J. Clin. Oncol., June 10, 2008; 26(17): 2846 - 2853.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Ma, Y. Qian, L. Wei, J. Abraham, X. Shi, V. Castranova, E. J. Harner, D. C. Flynn, and L. Guo
Population-Based Molecular Prognosis of Breast Cancer by Transcriptional Profiling
Clin. Cancer Res., April 1, 2007; 13(7): 2014 - 2022.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. E. Larsen, S. J. Pavey, L. H. Passmore, R. Bowman, B. E. Clarke, N. K. Hayward, and K. M. Fong
Expression profiling defines a recurrence signature in lung squamous cell carcinoma
Carcinogenesis, March 1, 2007; 28(3): 760 - 766.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. H. Cheng, C.-F. Horng, M. West, E. Huang, J. Pittman, M.-H. Tsou, H. Dressman, C.-M. Chen, S. Y. Tsai, J. J. Jian, et al.
Genomic Prediction of Locoregional Recurrence After Mastectomy in Breast Cancer
J. Clin. Oncol., October 1, 2006; 24(28): 4594 - 4602.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A.P.J.J. Bijnens, E. Lutgens, T. Ayoubi, J. Kuiper, A.J. Horrevoets, and M.J.A.P. Daemen
Genome-Wide Expression Studies of Atherosclerosis: Critical Issues in Methodology, Analysis, Interpretation of Transcriptomics Data
Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1226 - 1235.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Espinosa, J.A. F. Vara, A. Redondo, J.J. Sanchez, D. Hardisson, P. Zamora, F. G. Pastrana, P. Cejas, B. Martinez, A. Suarez, et al.
Breast Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study
J. Clin. Oncol., October 10, 2005; 23(29): 7278 - 7285.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.